Dermatology
Latest News
At 52 weeks, complete hair regrowth rates still climbing on deuruxolitinib
Complete responses continued to increase in open-label extensions of phase 3 alopecia areata studies.
Latest News
Actinic keratoses may predict skin cancers in older adults
AKs have been associated with a small risk for cutaneous SCC, but associations with risk for other skin cancers have not been well studied.
Latest News
Incipient ulceration may affect prognosis in primary melanoma
“Future editions of the AJCC staging system should consider acknowledging this interpretive challenge and provide guidance on how primary...
Latest News
AAD updates guidelines for managing AD with phototherapy and systemic therapies
The work group recommended the inclusion of active comparator arms in randomized, controlled trials as new systemic therapies continue to be...
Latest News
Specialty-trained pathologists more likely to make higher-grade diagnoses for melanocytic lesions
A total of 338 pathologists were included in the exploratory analysis; 225 were dermatopathologists.
Latest News
AI flagged skin cancer with near-perfect accuracy, in UK study
The researchers tested the AI by integrating it into a clinical diagnosis process - anticipating a future in which AI helps doctors catch skin...
Latest News
FDA proposes ban on hair straightener ingredients
The proposal specifies that formaldehyde would be banned, as well as other chemicals that release formaldehyde, such as methylene glycol.
Latest News
FDA approves bimekizumab for moderate to severe plaque psoriasis in adults
With this approval, bimekizumab becomes the only interleukin (IL)-17A and IL-17F inhibitor approved for the treatment of these patients.
Latest News
Once-weekly topical therapy shows promise for moderate to severe acne
In vitro studies have found that components of S. lacustris, a freshwater sponge, have effects that include antimicrobial activity...
Latest News
FDA approves nivolumab for resected stage IIB/C melanoma
Approval was based on findings from a phase 3 trial, which randomly assigned 790 patients to receive nivolumab or placebo by intravenous infusion...